Contineum Therapeutics (CTNM) Other financing activities (2023 - 2026)

Contineum Therapeutics' Other financing activities history runs 4 years deep, the most recent figure standing at $198000.0 for Q1 2026.

• On a quarterly basis, Other financing activities rose 725.0% year-over-year to $198000.0 in Q1 2026; TTM through Mar 2026 was $393000.0, a 28.01% increase from a year earlier, with the FY2025 full-year figure at $219000.0, down 45.93% from the prior year.
• Other financing activities climbed to $198000.0 in Q1 2026 per CTNM's latest filing, from $22000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $257000.0 in Q4 2024 and bottomed at -$122000.0 in Q2 2024.
• The 4-year median for Other financing activities is $24000.0 (2025), against an average of $63230.8.
• Biggest YoY gain for Other financing activities was 1425.0% in 2024; the steepest drop was 742.11% in 2024.
• Year by year, Other financing activities stood at -$109000.0 in 2023, then jumped by 335.78% to $257000.0 in 2024, then tumbled by 91.44% to $22000.0 in 2025, then soared by 800.0% to $198000.0 in 2026.
• Per Business Quant, the three latest CTNM Other financing activities figures stand at $198000.0 (Q1 2026), $22000.0 (Q4 2025), and -$70000.0 (Q3 2025).